03:27 AM EST, 11/05/2026 (MT Newswires) -- Novonesis (NSIS-B.CO) provided a sales growth outlook for the fourth quarter and maintained its guidance for the full year. The biotechnology company expects organic sales growth in the high single digits for the fourth quarter, it said Thursday. For 2026, it still expects organic sales growth of 7% to 8%, including a close to 1 percentage point negative effect from exiting certain countries.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.